Loading…
Reported covered position: Vice President
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Diagnostics Testing Preparedness Plan Act of 2025
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(HCR) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Alzheimer's and Influenza Preparedness
Diagnostics Testing Preparedness Plan Act of 2025
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES via F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
2026 · third_quarter · Q3
(MED) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Breast and Cervical Cancer, Alzheimer's and Influenza Preparedness Clinical Lab Fee Schedule reform, the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act H.R. 5269 / S. 2761 and Medicare coverage of FDA approved breakthrough diagnostics, S.1717 / H.R. 5343 The Ensuring Patient Access to Critical Breakthrough
Source: Senate LDA
(HCR) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Breast and Cervical Cancer, Alzheimer's and Influenza Preparedness
Diagnostics Testing Preparedness Plan Act of 2025
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MED) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Alzheimer's and Influenza Preparedness Clinical Lab Fee Schedule reform, the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act H.R. 5269 / S. 2761 and Medicare coverage of FDA approved breakthrough diagnostics, S.1717 / H.R. 5343 The Ensuring Patient Access to Critical Breakthrough
Diagnostics Testing Preparedness Plan Act of 2025
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(HCR) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Breast and Cervical Cancer, Alzheimer's and Influenza Preparedness
Diagnostics Testing Preparedness Plan Act of 2025
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MED) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Breast and Cervical Cancer, Alzheimer's and Influenza Preparedness Clinical Lab Fee Schedule reform, the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act H.R. 5269 / S. 2761 and Medicare coverage of FDA approved breakthrough diagnostics, S.1717 / H.R. 5343 The Ensuring Patient Access to Critical Breakthrough
Diagnostics Testing Preparedness Plan Act of 2025
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MED) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Breast and Cervical Cancer, Alzheimer's and Influenza Preparedness Clinical Lab Fee Schedule reform, the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act H.R. 5269 / S. 2761 and Medicare coverage of FDA approved breakthrough diagnostics, S.1717 / H.R. 5343 The Ensuring Patient Access to Critical Breakthrough
RESULTS Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
Access to and reimbursement of diagnostics in the Medicare program. H.R. 5269 / S. 2761 Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act - Issues related to Medicare reimbursement of Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) 2014. S.1717 / H.R.5343 The Ensuring Patient Access to Critical Breakthrough Products Act. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing transitional coverage period. Issues related to Tariffs and Department of Commerce 232 investigation on Medical Technologies FY2027 Appropriations for Labor, Health and Human Services, Education, and Related Agencies
RESULTS Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MED) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Breast and Cervical Cancer, Alzheimer's and Influenza Preparedness Clinical Lab Fee Schedule reform, the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act H.R. 5269 / S. 2761 and Medicare coverage of FDA approved breakthrough diagnostics, S.1717 / H.R. 5343 The Ensuring Patient Access to Critical Breakthrough
RESULTS Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
Access to and reimbursement of diagnostics in the Medicare program. H.R. 5269 / S. 2761 Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act - Issues related to Medicare reimbursement of Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) 2014. S.1717 / H.R.5343 The Ensuring Patient Access to Critical Breakthrough Products Act. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing transitional coverage period.
RESULTS Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MED) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Breast and Cervical Cancer, Alzheimer's and Influenza Preparedness Clinical Lab Fee Schedule reform, the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act H.R. 5269 / S. 2761 and Medicare coverage of FDA approved breakthrough diagnostics, S.1717 / H.R. 5343 The Ensuring Patient Access to Critical Breakthrough
RESULTS Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
Access to and reimbursement of diagnostics in the Medicare program. H.R. 5269 / S. 2761 Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act - Issues related to Medicare reimbursement of Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) 2014. S.1717 / H.R.5343 The Ensuring Patient Access to Critical Breakthrough Products Act. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing transitional coverage period. Issues related to Tariffs and Department of Commerce 232 investigation on Medical Technologies FY2027 Appropriations for Labor, Health and Human Services, Education, and Related Agencies
RESULTS Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MED) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Alzheimer's and Influenza Preparedness Clinical Lab Fee Schedule reform, the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act H.R. 5269 / S. 2761 and Medicare coverage of FDA approved breakthrough diagnostics, S.1717 / H.R. 5343 The Ensuring Patient Access to Critical Breakthrough
Ensuring Patient Access to Critical Breakthrough Products Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
Access to and reimbursement of diagnostics in the Medicare program. H.R. 5269 / S. 2761 Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act - Issues related to Medicare reimbursement of Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) 2014. S.1717 / H.R.5343 The Ensuring Patient Access to Critical Breakthrough Products Act. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing transitional coverage period. Issues related to Tariffs and Department of Commerce 232 investigation on Medical Technologies FY2027 Appropriations for Labor, Health and Human Services, Education, and Related Agencies
Ensuring Patient Access to Critical Breakthrough Products Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MED) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Breast and Cervical Cancer, Alzheimer's and Influenza Preparedness Clinical Lab Fee Schedule reform, the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act H.R. 5269 / S. 2761 and Medicare coverage of FDA approved breakthrough diagnostics, S.1717 / H.R. 5343 The Ensuring Patient Access to Critical Breakthrough
Ensuring Patient Access to Critical Breakthrough Products Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
Access to and reimbursement of diagnostics in the Medicare program. H.R. 5269 / S. 2761 Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act - Issues related to Medicare reimbursement of Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) 2014. S.1717 / H.R.5343 The Ensuring Patient Access to Critical Breakthrough Products Act. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing transitional coverage period. Issues related to Tariffs and Department of Commerce 232 investigation on Medical Technologies FY2027 Appropriations for Labor, Health and Human Services, Education, and Related Agencies
Ensuring Patient Access to Critical Breakthrough Products Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MED) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Breast and Cervical Cancer, Alzheimer's and Influenza Preparedness Clinical Lab Fee Schedule reform, the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act H.R. 5269 / S. 2761 and Medicare coverage of FDA approved breakthrough diagnostics, S.1717 / H.R. 5343 The Ensuring Patient Access to Critical Breakthrough
Ensuring Patient Access to Critical Breakthrough Products Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
Access to and reimbursement of diagnostics in the Medicare program. H.R. 5269 / S. 2761 Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act - Issues related to Medicare reimbursement of Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) 2014. S.1717 / H.R.5343 The Ensuring Patient Access to Critical Breakthrough Products Act. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing transitional coverage period.
Ensuring Patient Access to Critical Breakthrough Products Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MED) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Alzheimer's and Influenza Preparedness Clinical Lab Fee Schedule reform, the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act H.R. 5269 / S. 2761 and Medicare coverage of FDA approved breakthrough diagnostics, S.1717 / H.R. 5343 The Ensuring Patient Access to Critical Breakthrough
Ensuring Patient Access to Critical Breakthrough Products Act of 2025
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
Access to and reimbursement of diagnostics in the Medicare program. H.R. 5269 / S. 2761 Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act - Issues related to Medicare reimbursement of Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) 2014. S.1717 / H.R.5343 The Ensuring Patient Access to Critical Breakthrough Products Act. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing transitional coverage period. Issues related to Tariffs and Department of Commerce 232 investigation on Medical Technologies FY2027 Appropriations for Labor, Health and Human Services, Education, and Related Agencies
Ensuring Patient Access to Critical Breakthrough Products Act of 2025
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MED) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Breast and Cervical Cancer, Alzheimer's and Influenza Preparedness Clinical Lab Fee Schedule reform, the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act H.R. 5269 / S. 2761 and Medicare coverage of FDA approved breakthrough diagnostics, S.1717 / H.R. 5343 The Ensuring Patient Access to Critical Breakthrough
Ensuring Patient Access to Critical Breakthrough Products Act of 2025
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
Access to and reimbursement of diagnostics in the Medicare program. H.R. 5269 / S. 2761 Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act - Issues related to Medicare reimbursement of Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) 2014. S.1717 / H.R.5343 The Ensuring Patient Access to Critical Breakthrough Products Act. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing transitional coverage period. Issues related to Tariffs and Department of Commerce 232 investigation on Medical Technologies FY2027 Appropriations for Labor, Health and Human Services, Education, and Related Agencies
Ensuring Patient Access to Critical Breakthrough Products Act of 2025
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MED) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Breast and Cervical Cancer, Alzheimer's and Influenza Preparedness Clinical Lab Fee Schedule reform, the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act H.R. 5269 / S. 2761 and Medicare coverage of FDA approved breakthrough diagnostics, S.1717 / H.R. 5343 The Ensuring Patient Access to Critical Breakthrough
Ensuring Patient Access to Critical Breakthrough Products Act of 2025
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MED) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Alzheimer's and Influenza Preparedness Clinical Lab Fee Schedule reform, the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act H.R. 5269 / S. 2761 and Medicare coverage of FDA approved breakthrough diagnostics, S.1717 / H.R. 5343 The Ensuring Patient Access to Critical Breakthrough
Ensuring Patient Access to Critical Breakthrough Products Act of 2025
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
Access to and reimbursement of diagnostics in the Medicare program. H.R. 5269 / S. 2761 Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act - Issues related to Medicare reimbursement of Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) 2014. S.1717 / H.R.5343 The Ensuring Patient Access to Critical Breakthrough Products Act. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing transitional coverage period.
RESULTS Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MED) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Breast and Cervical Cancer, Alzheimer's and Influenza Preparedness Clinical Lab Fee Schedule reform, the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act H.R. 5269 / S. 2761 and Medicare coverage of FDA approved breakthrough diagnostics, S.1717 / H.R. 5343 The Ensuring Patient Access to Critical Breakthrough
RESULTS Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MED) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Breast and Cervical Cancer, Alzheimer's and Influenza Preparedness Clinical Lab Fee Schedule reform, the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act H.R. 5269 / S. 2761 and Medicare coverage of FDA approved breakthrough diagnostics, S.1717 / H.R. 5343 The Ensuring Patient Access to Critical Breakthrough
RESULTS Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
Access to and reimbursement of diagnostics in the Medicare program. H.R. 5269 / S. 2761 Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act - Issues related to Medicare reimbursement of Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) 2014. S.1717 / H.R.5343 The Ensuring Patient Access to Critical Breakthrough Products Act. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing transitional coverage period.
RESULTS Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
Access to and reimbursement of diagnostics in the Medicare program. H.R. 5269 / S. 2761 Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act - Issues related to Medicare reimbursement of Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) 2014. S.1717 / H.R.5343 The Ensuring Patient Access to Critical Breakthrough Products Act. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing transitional coverage period. Issues related to Tariffs and Department of Commerce 232 investigation on Medical Technologies FY2027 Appropriations for Labor, Health and Human Services, Education, and Related Agencies
RESULTS Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MED) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Alzheimer's and Influenza Preparedness Clinical Lab Fee Schedule reform, the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act H.R. 5269 / S. 2761 and Medicare coverage of FDA approved breakthrough diagnostics, S.1717 / H.R. 5343 The Ensuring Patient Access to Critical Breakthrough
RESULTS Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
Access to and reimbursement of diagnostics in the Medicare program. H.R. 5269 / S. 2761 Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act - Issues related to Medicare reimbursement of Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) 2014. S.1717 / H.R.5343 The Ensuring Patient Access to Critical Breakthrough Products Act. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing transitional coverage period. Issues related to Tariffs and Department of Commerce 232 investigation on Medical Technologies FY2027 Appropriations for Labor, Health and Human Services, Education, and Related Agencies
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
Access to and reimbursement of diagnostics in the Medicare program. Issues related to Medicare reimbursement of Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) 2014. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing transitional coverage period, including S.1717 The Ensuring Patient Access to Critical Breakthrough Products Act. Issues related to Corporate Tax and Tariffs, H.R.1 - One Big Beautiful Bill Act
Diagnostics Testing Preparedness Plan Act of 2025
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(HCR) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Alzheimer's and Influenza Preparedness
Diagnostics Testing Preparedness Plan Act of 2025
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MED) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Alzheimer's and Influenza Preparedness
Diagnostics Testing Preparedness Plan Act of 2025
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(HCR) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics
Diagnostics Testing Preparedness Plan Act of 2025
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(HCR) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Alzheimer's and Influenza Preparedness
Diagnostics Testing Preparedness Plan Act of 2025
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MED) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Alzheimer's and Influenza Preparedness
Diagnostics Testing Preparedness Plan Act of 2025
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(HCR) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Alzheimer's and Influenza Preparedness
Diagnostics Testing Preparedness Plan Act of 2025
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MED) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Alzheimer's and Influenza Preparedness
Diagnostics Testing Preparedness Plan Act of 2025
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MED) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Clinical Lab Fee Schedule reform and Medicare coverage of FDA approved breakthrough diagnostics and innovative diagnostics
RESULTS Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
Access to and reimbursement of diagnostics in the Medicare program. H.R. 5269 / S. 2761 Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act - Issues related to Medicare reimbursement of Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) 2014. S.1717 / H.R.5343 The Ensuring Patient Access to Critical Breakthrough Products Act. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing transitional coverage period Issues related to Tariffs
RESULTS Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
Access to and reimbursement of diagnostics in the Medicare program. H.R. 5269 / S. 2761 Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act - Issues related to Medicare reimbursement of Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) 2014. S.1717 / H.R.5343 The Ensuring Patient Access to Critical Breakthrough Products Act. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing transitional coverage period Issues related to Tariffs
Ensuring Patient Access to Critical Breakthrough Products Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
Access to and reimbursement of diagnostics in the Medicare program. H.R. 5269 / S. 2761 Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act - Issues related to Medicare reimbursement of Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) 2014. S.1717 / H.R.5343 The Ensuring Patient Access to Critical Breakthrough Products Act. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing transitional coverage period Issues related to Tariffs
Ensuring Patient Access to Critical Breakthrough Products Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
Access to and reimbursement of diagnostics in the Medicare program. H.R. 5269 / S. 2761 Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act - Issues related to Medicare reimbursement of Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) 2014. S.1717 / H.R.5343 The Ensuring Patient Access to Critical Breakthrough Products Act. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing transitional coverage period Issues related to Tariffs
Ensuring Patient Access to Critical Breakthrough Products Act of 2025
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
Access to and reimbursement of diagnostics in the Medicare program. Issues related to Medicare reimbursement of Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) 2014. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing transitional coverage period, including S.1717 The Ensuring Patient Access to Critical Breakthrough Products Act. Issues related to Corporate Tax and Tariffs, H.R.1 - One Big Beautiful Bill Act
Ensuring Patient Access to Critical Breakthrough Products Act of 2025
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
Access to and reimbursement of diagnostics in the Medicare program. H.R. 5269 / S. 2761 Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act - Issues related to Medicare reimbursement of Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) 2014. S.1717 / H.R.5343 The Ensuring Patient Access to Critical Breakthrough Products Act. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing transitional coverage period Issues related to Tariffs
Ensuring Patient Access to Critical Breakthrough Products Act of 2025
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
Access to and reimbursement of diagnostics in the Medicare program. H.R. 5269 / S. 2761 Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act - Issues related to Medicare reimbursement of Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) 2014. S.1717 / H.R.5343 The Ensuring Patient Access to Critical Breakthrough Products Act. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing transitional coverage period Issues related to Tariffs
RESULTS Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
Access to and reimbursement of diagnostics in the Medicare program. H.R. 5269 / S. 2761 Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act - Issues related to Medicare reimbursement of Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) 2014. S.1717 / H.R.5343 The Ensuring Patient Access to Critical Breakthrough Products Act. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing transitional coverage period Issues related to Tariffs
RESULTS Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
Access to and reimbursement of diagnostics in the Medicare program. H.R. 5269 / S. 2761 Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act - Issues related to Medicare reimbursement of Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) 2014. S.1717 / H.R.5343 The Ensuring Patient Access to Critical Breakthrough Products Act. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing transitional coverage period Issues related to Tariffs
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MMM) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA), and H.R. 1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MMM) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA), and HR 1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
H.R. 2369 The Verifying Accurate Leading-edge IVCT Development Act, Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act, H. R. 5846 Protecting America from Seasonal and Pandemic, Influenza Act of 2023 (the Influenza Act) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA) and H.R. 1691 the Ensuring Patient Access to Critical Breakthrough Products Act of 2023 FY25 Labor, Health and Human Services, Education, and Related Agencies Appropriations Act
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA) and H.R. 1691 the Ensuring Patient Access to Critical Breakthrough Products Act of 2023 FY25 Labor, Health and Human Services, Education, and Related Agencies Appropriations Act
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MMM) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA), and S. 5349/ H.R. 1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023. Issues related to the coverage of neurology markers on the Clinical Lab Fee Schedule
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MMM) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA), and S. 5349/ H.R. 1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023. Issues related to the coverage of neurology markers on the Clinical Lab Fee Schedule
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MMM) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA), and H.R. 1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023
VALID Act of 2023
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
H.R. 2369 The Verifying Accurate Leading-edge IVCT Development Act, Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act, H. R. 5846 Protecting America from Seasonal and Pandemic, Influenza Act of 2023 (the Influenza Act) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA) and H.R. 1691 the Ensuring Patient Access to Critical Breakthrough Products Act of 2023 FY25 Labor, Health and Human Services, Education, and Related Agencies Appropriations Act
VALID Act of 2023
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(HCR) H.R. 2369 The Verifying Accurate Leading-edge IVCT Development Act, Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act, and H. R. 5846 Protecting America from Seasonal and Pandemic Influenza Act of 2023 (the Influenza Act)
VALID Act of 2023
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
H.R. 2369 The Verifying Accurate Leading-edge IVCT Development Act, Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act, H. R. 5846 Protecting America from Seasonal and Pandemic, Influenza Act of 2023 (the Influenza Act) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA) and 1691 the Ensuring Patient Access to Critical Breakthrough Products Act of 2023
VALID Act of 2023
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(HCR) H.R. 2369 The Verifying Accurate Leading-edge IVCT Development Act, Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act, and H. R. 5846 Protecting America from Seasonal and Pandemic Influenza Act of 2023 (the Influenza Act) FY25 Labor, Health and Human Services, Education, and Related Agencies Appropriations Act
Saving Access to Laboratory Services Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MMM) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA), and S. 5349/ H.R. 1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023. Issues related to the coverage of neurology markers on the Clinical Lab Fee Schedule
Saving Access to Laboratory Services Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MMM) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA), and S. 5349/ H.R. 1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023. Issues related to the coverage of neurology markers on the Clinical Lab Fee Schedule
Saving Access to Laboratory Services Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
H.R. 2369 The Verifying Accurate Leading-edge IVCT Development Act, Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act, H. R. 5846 Protecting America from Seasonal and Pandemic, Influenza Act of 2023 (the Influenza Act) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA) and 1691 the Ensuring Patient Access to Critical Breakthrough Products Act of 2023
Saving Access to Laboratory Services Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MMM) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA), and HR 1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023
Saving Access to Laboratory Services Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MMM) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA), and H.R. 1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023
Saving Access to Laboratory Services Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
H.R. 2369 The Verifying Accurate Leading-edge IVCT Development Act, Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act, H. R. 5846 Protecting America from Seasonal and Pandemic, Influenza Act of 2023 (the Influenza Act) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA) and H.R. 1691 the Ensuring Patient Access to Critical Breakthrough Products Act of 2023 FY25 Labor, Health and Human Services, Education, and Related Agencies Appropriations Act
Saving Access to Laboratory Services Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA) and H.R. 1691 the Ensuring Patient Access to Critical Breakthrough Products Act of 2023 FY25 Labor, Health and Human Services, Education, and Related Agencies Appropriations Act
Saving Access to Laboratory Services Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MMM) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA), and H.R. 1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023
State Strategic Stockpile Act of 2023
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
H.R. 2369 The Verifying Accurate Leading-edge IVCT Development Act, Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act, H. R. 5846 Protecting America from Seasonal and Pandemic, Influenza Act of 2023 (the Influenza Act) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA) and 1691 the Ensuring Patient Access to Critical Breakthrough Products Act of 2023
State Strategic Stockpile Act of 2023
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(HCR) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act. FY25 Labor, Health and Human Services, Education, and Related Agencies Appropriations Act
State Strategic Stockpile Act of 2023
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(HCR) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act. Issues related to the regulation of diagnostics
State Strategic Stockpile Act of 2023
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(HCR) H.R. 2369 The Verifying Accurate Leading-edge IVCT Development Act, Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act, and H. R. 5846 Protecting America from Seasonal and Pandemic Influenza Act of 2023 (the Influenza Act) FY25 Labor, Health and Human Services, Education, and Related Agencies Appropriations Act
State Strategic Stockpile Act of 2023
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
H.R. 2369 The Verifying Accurate Leading-edge IVCT Development Act, Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act, H. R. 5846 Protecting America from Seasonal and Pandemic, Influenza Act of 2023 (the Influenza Act) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA) and H.R. 1691 the Ensuring Patient Access to Critical Breakthrough Products Act of 2023 FY25 Labor, Health and Human Services, Education, and Related Agencies Appropriations Act
State Strategic Stockpile Act of 2023
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(HCR) H.R. 2369 The Verifying Accurate Leading-edge IVCT Development Act, Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act, and H. R. 5846 Protecting America from Seasonal and Pandemic Influenza Act of 2023 (the Influenza Act)
To amend the Public Health Service Act to require the development of a diagnostic testing preparedness plan to be used during public health emergencies, and for other purposes.
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
H.R. 2369 The Verifying Accurate Leading-edge IVCT Development Act, Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act, H. R. 5846 Protecting America from Seasonal and Pandemic, Influenza Act of 2023 (the Influenza Act) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA) and H.R. 1691 the Ensuring Patient Access to Critical Breakthrough Products Act of 2023 FY25 Labor, Health and Human Services, Education, and Related Agencies Appropriations Act
To amend the Public Health Service Act to require the development of a diagnostic testing preparedness plan to be used during public health emergencies, and for other purposes.
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
H.R. 2369 The Verifying Accurate Leading-edge IVCT Development Act, Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act, H. R. 5846 Protecting America from Seasonal and Pandemic, Influenza Act of 2023 (the Influenza Act) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA) and 1691 the Ensuring Patient Access to Critical Breakthrough Products Act of 2023
To amend the Public Health Service Act to require the development of a diagnostic testing preparedness plan to be used during public health emergencies, and for other purposes.
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(HCR) H.R. 2369 The Verifying Accurate Leading-edge IVCT Development Act, Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act, and H. R. 5846 Protecting America from Seasonal and Pandemic Influenza Act of 2023 (the Influenza Act) FY25 Labor, Health and Human Services, Education, and Related Agencies Appropriations Act
To amend the Public Health Service Act to require the development of a diagnostic testing preparedness plan to be used during public health emergencies, and for other purposes.
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(HCR) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act. FY25 Labor, Health and Human Services, Education, and Related Agencies Appropriations Act
To amend the Public Health Service Act to require the development of a diagnostic testing preparedness plan to be used during public health emergencies, and for other purposes.
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(HCR) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act. Issues related to the regulation of diagnostics
To amend the Public Health Service Act to require the development of a diagnostic testing preparedness plan to be used during public health emergencies, and for other purposes.
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(HCR) H.R. 2369 The Verifying Accurate Leading-edge IVCT Development Act, Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act, and H. R. 5846 Protecting America from Seasonal and Pandemic Influenza Act of 2023 (the Influenza Act)
Protecting America from Seasonal and Pandemic Influenza Act of 2023
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
H.R. 2369 The Verifying Accurate Leading-edge IVCT Development Act, Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act, H. R. 5846 Protecting America from Seasonal and Pandemic, Influenza Act of 2023 (the Influenza Act) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA) and H.R. 1691 the Ensuring Patient Access to Critical Breakthrough Products Act of 2023 FY25 Labor, Health and Human Services, Education, and Related Agencies Appropriations Act
Protecting America from Seasonal and Pandemic Influenza Act of 2023
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
H.R. 2369 The Verifying Accurate Leading-edge IVCT Development Act, Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act, H. R. 5846 Protecting America from Seasonal and Pandemic, Influenza Act of 2023 (the Influenza Act) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA) and 1691 the Ensuring Patient Access to Critical Breakthrough Products Act of 2023
Protecting America from Seasonal and Pandemic Influenza Act of 2023
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(HCR) H.R. 2369 The Verifying Accurate Leading-edge IVCT Development Act, Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act, and H. R. 5846 Protecting America from Seasonal and Pandemic Influenza Act of 2023 (the Influenza Act) FY25 Labor, Health and Human Services, Education, and Related Agencies Appropriations Act
Protecting America from Seasonal and Pandemic Influenza Act of 2023
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(HCR) H.R. 2369 The Verifying Accurate Leading-edge IVCT Development Act, Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act, and H. R. 5846 Protecting America from Seasonal and Pandemic Influenza Act of 2023 (the Influenza Act)
Saving Access to Laboratory Services Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MMM) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA), and H.R. 1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023
Saving Access to Laboratory Services Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MMM) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA), and H.R. 1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023
Saving Access to Laboratory Services Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
H.R. 2369 The Verifying Accurate Leading-edge IVCT Development Act, Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act, H. R. 5846 Protecting America from Seasonal and Pandemic, Influenza Act of 2023 (the Influenza Act) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA) and H.R. 1691 the Ensuring Patient Access to Critical Breakthrough Products Act of 2023 FY25 Labor, Health and Human Services, Education, and Related Agencies Appropriations Act
Saving Access to Laboratory Services Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MMM) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA), and S. 5349/ H.R. 1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023. Issues related to the coverage of neurology markers on the Clinical Lab Fee Schedule
Saving Access to Laboratory Services Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MMM) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA), and S. 5349/ H.R. 1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023. Issues related to the coverage of neurology markers on the Clinical Lab Fee Schedule
Saving Access to Laboratory Services Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
H.R. 2369 The Verifying Accurate Leading-edge IVCT Development Act, Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act, H. R. 5846 Protecting America from Seasonal and Pandemic, Influenza Act of 2023 (the Influenza Act) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA) and 1691 the Ensuring Patient Access to Critical Breakthrough Products Act of 2023
Saving Access to Laboratory Services Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA) and H.R. 1691 the Ensuring Patient Access to Critical Breakthrough Products Act of 2023 FY25 Labor, Health and Human Services, Education, and Related Agencies Appropriations Act
Saving Access to Laboratory Services Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MMM) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA), and HR 1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MMM) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA), and S. 5349/ H.R. 1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023. Issues related to the coverage of neurology markers on the Clinical Lab Fee Schedule
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MMM) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA), and S. 5349/ H.R. 1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023. Issues related to the coverage of neurology markers on the Clinical Lab Fee Schedule
SUPER BUGS Act of 2023
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(HCR) H.R. 2369 The Verifying Accurate Leading-edge IVCT Development Act, H. R. 1305 Saving Us from Pandemic Era Resistance by Building a Unified Global Strategy Act of 2023", Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act, H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act, H.R.3723 Medical Device Electronic Labeling Act, and influenza preparedness
SUPER BUGS Act of 2023
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
H.R. 2369 The Verifying Accurate Leading-edge IVCT Development Act, Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act, H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act. (HCR) H. R. 1305 Saving Us from Pandemic Era Resistance by Building a Unified Global Strategy Act of 2023", and issues related to influenzas preparedness Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA)
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MMM) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA), and HR 1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MMM) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA), and HR 1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MMM) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA), and HR 1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MMM) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA), and HR 1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023
VALID Act of 2023
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
H.R. 2369 The Verifying Accurate Leading-edge IVCT Development Act, Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act, H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act. (HCR) H. R. 1305 Saving Us from Pandemic Era Resistance by Building a Unified Global Strategy Act of 2023", and issues related to influenzas preparedness Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA)
(HCR) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Breast and Cervical Cancer, Alzheimer's and Influenza Preparedness
Issues related to Tariffs and Department of Commerce 232 investigation on Medical Technologies
Access to and reimbursement of diagnostics in the Medicare program. H.R. 5269 / S. 2761 Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act - Issues related to Medicare reimbursement of Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) 2014. S.1717 / H.R.5343 The Ensuring Patient Access to Critical Breakthrough Products Act. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing transitional coverage period.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES via F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
2026 · second_quarter · Q2
Access to and reimbursement of diagnostics in the Medicare program. H.R. 5269 / S. 2761 Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act - Issues related to Medicare reimbursement of Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) 2014. S.1717 / H.R.5343 The Ensuring Patient Access to Critical Breakthrough Products Act. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing transitional coverage period. Issues related to Tariffs and Department of Commerce 232 investigation on Medical Technologies FY2027 Appropriations for Labor, Health and Human Services, Education, and Related Agencies
(MED) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Breast and Cervical Cancer, Alzheimer's and Influenza Preparedness Clinical Lab Fee Schedule reform, the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act H.R. 5269 / S. 2761 and Medicare coverage of FDA approved breakthrough diagnostics, S.1717 / H.R. 5343 The Ensuring Patient Access to Critical Breakthrough
(HCR) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Breast and Cervical Cancer, Alzheimer's and Influenza Preparedness
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES via F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
2026 · first_quarter · Q1
(HCR) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Alzheimer's and Influenza Preparedness
(MED) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Alzheimer's and Influenza Preparedness Clinical Lab Fee Schedule reform, the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act H.R. 5269 / S. 2761 and Medicare coverage of FDA approved breakthrough diagnostics, S.1717 / H.R. 5343 The Ensuring Patient Access to Critical Breakthrough
Access to and reimbursement of diagnostics in the Medicare program. H.R. 5269 / S. 2761 Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act - Issues related to Medicare reimbursement of Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) 2014. S.1717 / H.R.5343 The Ensuring Patient Access to Critical Breakthrough Products Act. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing transitional coverage period. Issues related to Tariffs and Department of Commerce 232 investigation on Medical Technologies FY2027 Appropriations for Labor, Health and Human Services, Education, and Related Agencies
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES via F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
2025 · fourth_quarter · Q4
Access to and reimbursement of diagnostics in the Medicare program. H.R. 5269 / S. 2761 Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act - Issues related to Medicare reimbursement of Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) 2014. S.1717 / H.R.5343 The Ensuring Patient Access to Critical Breakthrough Products Act. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing transitional coverage period Issues related to Tariffs
(HCR) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Alzheimer's and Influenza Preparedness
(MED) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Alzheimer's and Influenza Preparedness
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES via F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
2025 · third_quarter · Q3
Access to and reimbursement of diagnostics in the Medicare program. H.R. 5269 / S. 2761 Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act - Issues related to Medicare reimbursement of Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) 2014. S.1717 / H.R.5343 The Ensuring Patient Access to Critical Breakthrough Products Act. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing transitional coverage period Issues related to Tariffs
(HCR) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Alzheimer's and Influenza Preparedness
(MED) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Alzheimer's and Influenza Preparedness
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES via F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
2025 · second_quarter · Q2
Access to and reimbursement of diagnostics in the Medicare program. Issues related to Medicare reimbursement of Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) 2014. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing transitional coverage period, including S.1717 The Ensuring Patient Access to Critical Breakthrough Products Act. Issues related to Corporate Tax and Tariffs, H.R.1 - One Big Beautiful Bill Act
(HCR) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Alzheimer's and Influenza Preparedness
F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES via F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
2025 · first_quarter · Q1
(HCR) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics
(MED) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Clinical Lab Fee Schedule reform and Medicare coverage of FDA approved breakthrough diagnostics and innovative diagnostics
F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES via F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
2024 · fourth_quarter · Q4
(MMM) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA), and S. 5349/ H.R. 1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023. Issues related to the coverage of neurology markers on the Clinical Lab Fee Schedule
(MMM) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA), and S. 5349/ H.R. 1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023. Issues related to the coverage of neurology markers on the Clinical Lab Fee Schedule
F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES via F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
2024 · third_quarter · Q3
FOR: Support authorization and appropriations for President's Emergency Plan for AIDS Relief (PEPFAR)
(HCR) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act. FY25 Labor, Health and Human Services, Education, and Related Agencies Appropriations Act
(MMM) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA), and H.R. 1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023
F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES via F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
2024 · second_quarter · Q2
(MMM) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA), and H.R. 1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023
FOR: Support authorization and appropriations for President's Emergency Plan for AIDS Relief (PEPFAR)
(HCR) H.R. 2369 The Verifying Accurate Leading-edge IVCT Development Act, Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act, and H. R. 5846 Protecting America from Seasonal and Pandemic Influenza Act of 2023 (the Influenza Act) FY25 Labor, Health and Human Services, Education, and Related Agencies Appropriations Act
F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES via F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
2024 · first_quarter · Q1
FOR: Support authorization and appropriations for President's Emergency Plan for AIDS Relief (PEPFAR)
H.R. 2369 The Verifying Accurate Leading-edge IVCT Development Act, Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act, H. R. 5846 Protecting America from Seasonal and Pandemic, Influenza Act of 2023 (the Influenza Act) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA) and 1691 the Ensuring Patient Access to Critical Breakthrough Products Act of 2023
F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES via F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
2023 · fourth_quarter · Q4
(HCR) H.R. 2369 The Verifying Accurate Leading-edge IVCT Development Act, Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act, SCREENS Act (HR 3916), issues related to 3rd party servicing of medical equipment (Right to Repair), and H. R. 5846 Protecting America from Seasonal and Pandemic Influenza Act of 2023 (the Influenza Act)
(MMM) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA), and HR 1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023
F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES via F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
2023 · third_quarter · Q3
(HCR) H.R. 2369 The Verifying Accurate Leading-edge IVCT Development Act, H. R. 1305 Saving Us from Pandemic Era Resistance by Building a Unified Global Strategy Act of 2023", Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act, H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act, H.R.3723 Medical Device Electronic Labeling Act, and influenza preparedness
(MMM) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA), and HR 1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023
F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES via F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
2023 · second_quarter · Q2
FOR: Reauthorization of President's Emergency Plan for AIDS Relief (PEPFAR)
(HCR) H.R. 2369 The Verifying Accurate Leading-edge IVCT Development Act, Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act, H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act, H.R.3723 Medical Device Electronic Labeling Act, and influenza preparedness
(MMM) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA), and HR 1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023
F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES via F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
2023 · first_quarter · Q1
(MMM) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA)
FOR: Reauthorization of President's Emergency Plan for AIDS Relief (PEPFAR)
(MED) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act
F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES via F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
2022 · fourth_quarter · Q4
MED: H.R. 2617 Consolidated Appropriations Act, 2023, H.R. 4128/S. 2209, The Verifying Accurate Leading-edge IVCT Development Act. Issues related to public health emergency preparedness, including S. 3799 PREVENT Pandemics Act and Pandemic All Hazards Preparedness Act Reauthorization
(MMM): H.R. 2617 Consolidated Appropriations Act, 2023, H.R. 4128/S. 2209 and Clinical Lab Fee Schedule S.4449 / HR 8188 Saving Access to Laboratory Services Act (SALSA)
HCR: H.R. 2617 Consolidated Appropriations Act, 2023, H.R. 4128/S. 2209, The Verifying Accurate Leading-edge IVCT Development Act. Issues related to public health emergency preparedness, including S. 3799 PREVENT Pandemics Act and Pandemic All Hazards Preparedness Act Reauthorization
F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES via F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
2022 · third_quarter · Q3
(MMM) Clinical Lab Fee Schedule S.4449 / HR 8188 Saving Access to Laboratory Services Act (SALSA)
(MED and HCR): S.4348 FDASLA Act of 2022/ H.R. 7667 Food and Drug Amendments of 2022, H.R. 4128/S. 2209 The Verifying Accurate Leading-edge IVCT Development Act, H.R. 6000 CURES Act. Issues related to public health emergency preparedness, including S. 3799 PREVENT Pandemics Act
(MED and HCR): S.4348 FDASLA Act of 2022/ H.R. 7667 Food and Drug Amendments of 2022, H.R. 4128/S. 2209 The Verifying Accurate Leading-edge IVCT Development Act, H.R. 6000 CURES Act. Issues related to public health emergency preparedness, including S. 3799 PREVENT Pandemics Act
F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES via F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
2022 · second_quarter · Q2
(HCR): S.4348 FDASLA Act of 2022/ H.R. 7667 Food and Drug Amendments of 2022, H.R. 4128/S. 2209 The Verifying Accurate Leading-edge IVCT Development Act, H.R. 6000 CURES Act. Issues related to public health emergency preparedness, including S. 3799 PREVENT Pandemics Act
(MMM) Clinical Lab Fee Schedule S.4449 / HR 8188 Saving Access to Laboratory Services Act (SALSA)
(MED): S.4348 FDASLA Act of 2022/ H.R. 7667 Food and Drug Amendments of 2022, H.R. 4128/S. 2209 The Verifying Accurate Leading-edge IVCT Development Act, H.R. 6000 CURES Act. Issues related to public health emergency preparedness, including S. 3799 PREVENT Pandemics Act
F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES via F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
2022 · first_quarter · Q1
H.R. 4128/S. 2209 The Verifying Accurate Leading-edge IVCT Development Act, H.R. 6000 CURES Act. Issues related to public health emergency preparedness, including S. 3799 PREVENT Pandemics Act
H.R. 4128/S. 2209 The Verifying Accurate Leading-edge IVCT Development Act, H.R. 6000 CURES Act. Issues related to public health emergency preparedness, including S. 3799 PREVENT Pandemics Act
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE, White House Office
F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES via F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
2021 · fourth_quarter · Q4
H.R. 4128/S. 2209 The Verifying Accurate Leading-edge IVCT Development Act Issues related to public health emergency preparedness
Issues relating to Medicare clinical laboratory fee schedule payment reductions and data reporting (S.610-Protecting Medicare and American Farmers from Sequester Cuts Act)
H.R. 4128/S. 2209 The Verifying Accurate Leading-edge IVCT Development Act. Issues related to public health emergency preparedness
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE, White House Office
F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES via F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
2021 · third_quarter · Q3
Medicare payment for clinical laboratories and diagnostic tests. (MMM): H.R.3 - Elijah E. Cummings Lower Drug Costs Now Act Prescription Drug pricing
H.R. 4128/S. 2209 The Verifying Accurate Leading-edge IVCT Development Act. H.R. 747/S.1018 The Access to Technology and Equipment for Same-day Tests Act. H.R.1436/S. 308 Protecting Providers Everywhere in America Act. H.R. 3635/S. 1974 Strengthening America's Strategic National Stockpile Act H.R. 3463/S.1693 Medical Supplies for Pandemics Act. Build Back Better Reconciliation Package Issues related to public health emergency preparedness
F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES via F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
2021 · second_quarter · Q2
H.R. 4128/S. 2209 The Verifying Accurate Leading-edge IVCT Development Act. H.R. 747/S.1018 The Access to Technology and Equipment for Same-day Tests Act. H.R.1436/S. 308 Protecting Providers Everywhere in America Act. H.R. 3635/S. 1974 Strengthening America's Strategic National Stockpile Act H.R. 3463/S.1693 Medical Supplies for Pandemics Act. Issues related to public health emergency preparedness
H.R. 4128/S. 2209 The Verifying Accurate Leading-edge IVCT Development Act. H.R. 747/S.1018 The Access to Technology and Equipment for Same-day Tests Act. H.R.1436/S. 308 Protecting Providers Everywhere in America Act. H.R. 3635/S. 1974 Strengthening America's Strategic National Stockpile Act H.R. 3463/S.1693 Medical Supplies for Pandemics Act. Issues related to public health emergency preparedness
F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES via F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
2021 · first_quarter · Q1
The Verifying Accurate, Leading-edge IVCT Development Act draft legislation.
H.R.1319 - American Rescue Plan legislation H.R.747 - The Access to Technology and Equipment for Same-day Tests Act. The Verifying Accurate, Leading-edge IVCT Development Act draft legislation.
none
F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES via F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
2020 · fourth_quarter · Q4
H.R. 6102/S.3404 - The Verifying Accurate, Leading-edge IVCT Development Act; S.1895 - The Lower Health Care Costs Act; H.R.861 - End Surprise Billing Act of 2019. HR 4393- Advancing Access to Precision Medicine Act. HR 6201- Families First Coronavirus Response Act; HR 748 - Coronavirus Aid, Relief, and Economic Security Act
Appropriations for Department of Health and Human Services and Department of Veterans Affairs.
MMM: Medicare payment for clinical laboratories and diagnostic tests; Medicare payment for patient self testing for prothrombin time; HR 3584 and S.3049, Laboratory Access for Beneficiaries Act
F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES via F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
2020 · third_quarter · Q3
Appropriations for Department of Health and Human Services and Department of Veterans Affairs
Medicare payment for clinical laboratories and diagnostic tests; Medicare payment for patient self testing for prothrombin time; HR 3584 and S.3049, Laboratory Access for Beneficiaries Act
Medical Device Tax
F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES via F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
2020 · second_quarter · Q2
Medical Device Tax
H.R. 6102/S.3404 - The Verifying Accurate, Leading-edge IVCT Development Act; S.1895 - The Lower Health Care Costs Act; H.R.861 - End Surprise Billing Act of 2019. HR 4393- Advancing Access to Precision Medicine Act. HR 6201- Families First Coronavirus Response Act; HR 748 - Coronavirus Aid, Relief, and Economic Security Act)
H.R. 6102/S.3404 - The Verifying Accurate, Leading-edge IVCT Development Act; S.1895 - The Lower Health Care Costs Act; H.R.861 - End Surprise Billing Act of 2019. HR 4393- Advancing Access to Precision Medicine Act. HR 6201- Families First Coronavirus Response Act; HR 748 - Coronavirus Aid, Relief, and Economic Security Act
F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES via F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
2020 · first_quarter · Q1
H.R. 6102/S.3404 - The Verifying Accurate, Leading-edge IVCT Development Act; S.1895 - The Lower Health Care Costs Act; H.R.861 - End Surprise Billing Act of 2019. HR 4393- Advancing Access to Precision Medicine Act. HR 6201- Families First Coronavirus Response Act; HR 748 - Coronavirus Aid, Relief, and Economic Security Act
Medical Device Tax
Medicare payment for clinical laboratories and diagnostic tests; Medicare payment for patient self testing for prothrombin time; HR 3584 and S.3049, Laboratory Access for Beneficiaries Act
F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES via F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
2019 · fourth_quarter · Q4
Appropriations for Department of Health and Human Services and Department of Veterans Affairs
H.R. xxxx - Discussion drafts of the Verifying Accurate, Leading-edge IVCT Development Act; S.1895 - The Lower Health Care Costs Act; H.R.861 - End Surprise Billing Act of 2019. HR 4393- Advancing Access to Precision Medicine Act
Medical Device Tax
F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES via F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
2019 · third_quarter · Q3
H.R. xxxx - Discussion drafts of the Verifying Accurate, Leading-edge IVCT Development Act; S.1895 - The Lower Health Care Costs Act; H.R.861 - End Surprise Billing Act of 2019.
Medical Device Tax
Medicare payment for clinical laboratories and diagnostic tests; Medicare payment for patient self testing for prothrombin time; HR 3584, Laboratory Access for Beneficiaries Act)
F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES via F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
2019 · second_quarter · Q2
MED and HCR: H.R. xxxx - Discussion drafts of the Verifying Accurate, Leading-edge IVCT Development Act; And, HR 6378 / S. 2852, Pandemic All-Hazards Preparedness Reauthorizatoin Act; And, S. 3476 - The PEPFAR Extension Act of 2018
MMM: Medicare payment for clinical laboratories and diagnostic tests; Medicare payment for patient self testing for prothrombin time; HR 3584, Laboratory Access for Beneficiaries Act)
MED and HCR: H.R. xxxx - Discussion drafts of the Verifying Accurate, Leading-edge IVCT Development Act; And, HR 6378 / S. 2852, Pandemic All-Hazards Preparedness Reauthorizatoin Act; And, S. 3476 - The PEPFAR Extension Act of 2018;
F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES via F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
2019 · first_quarter · Q1
H.R. xxxx - Discussion drafts of the Diagnostic Accuracy and Innovation Act and the Verifying Accurate, Leading-edge IVCT Development Act; And, HR 6378 / S. 2852, Pandemic All-Hazards Preparedness Reauthorizatoin Act; And, S. 3476 - The PEPFAR Extension Act of 2018).
MMM: Medicare payment for clinical laboratories and diagnostic tests. Medicare payment for patient self testing for prothrombin time. Protecting Access to Medicare Act of 2014
H.R. xxxx - Discussion drafts of the Diagnostic Accuracy and Innovation Act and the Verifying Accurate, Leading-edge IVCT Development Act; And, HR 6378 / S. 2852, Pandemic All-Hazards Preparedness Reauthorizatoin Act; And, S. 3476 - The PEPFAR Extension Act of 2018
F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES via F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
2018 · fourth_quarter · Q4
Issues: - Medical Device Tax
H.R. 4302 - Protecting Access to Medicare Act of 2014. Medicare physician fee schedule for patient self-testing prothrombin time; Competitive bidding program for diabetes testing supplies.
H.R. xxxx - Regulatory framework for in-vitro clinical tests (Diagnostic Accuracy and Innovation Act and Verifying Accurate, Leading-edge IVCT Development Act) HR 6378 / S. 2852 Pandemic All-Hazards Preparedness Reauthorization Act; Medicare payment for clinical laboratories and diagnostic tests, and Protecting Access to Medicare Act of 2014.
- S. 3476 - The PEPFAR Extension Act of 2018.

F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES via F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
2018 · third_quarter · Q3
Medical Device Tax
H.R. xxxx - Regulatory framework for in-vitro clinical tests (discussion draft, and Diagnostic Accuracy and Innovation Act). HR 6378 / S. 2852 Pandemic All-Hazards Preparedness Reauthorization Act; USPSTF Cervical Cancer Screening Recommendation. H.R. 4302- Protecting Access to Medicare Act of 2014
H.R. 4302 - Protecting Access to Medicare Act of 2014 Competitive bidding program for diabetic testing supplies. Medicare physician fee schedule for patient self-testing prothrombin time
F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES via F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
2018 · second_quarter · Q2
H.R. xxxx - Regulatory framework for in-vitro clinical tests (discussion draft, and Diagnostic Accuracy and Innovation Act). HR 6378 / S. 2852 Pandemic All-Hazards Preparedness Reauthorization Act; USPSTF Cervical Cancer Screening Recommendation. H.R. 4302- Protecting Access to Medicare Act of 2014
Medical Device Tax
H.R. 5786/S. 3024: Military Construction, Veterans Affairs, and Related Agencies Appropriations Bill 2019 H.R. xxxx /S. 3158: Department of Labor, Health, and Human Services, and Education, and Related Agencies Appropriations Bill 2019
F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES via F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
2018 · first_quarter · Q1
H.R.1892 - Bipartisan Budget Act of 2018 H.R. 3271 and S.1914 - Protecting Access to Diabetic Testing Supplies Act of 2017. H.R. xxxx - Regulatory framework for in-vitro clinical tests (unnamed discussion draft, and Diagnostic Accuracy and Innovation Act). H.R. 4302 - Protecting Access to Medicare Act of 2014; HR xxxx Pandemic All-Hazards Preparedness Reauthorization Act; USPSTF Cervical Cancer Screening Recommendation.
Medical Device Tax; H.R.1892 - Bipartisan Budget Act of 2018;
S.1914 - Protecting Access to Diabetic Testing Supplies Act of 2017
F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES via F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
2017 · fourth_quarter · Q4
H.R. 3271- S.1914 - Protecting Access to Diabetic Testing Supplies Act of 2017 H.R. xxxx - Regulatory framework for in-vitro clinical tests (unnamed discussion draft, and Diagnostic Accuracy and Innovation Act).
H.R. 3271 and S.1914 - Protecting Access to Diabetic Testing Supplies Act of 2017.
H.R. 4302 - Protecting Access to Medicare Act of 2014 H.R. 3271 and S.1914 - Protecting Access to Diabetic Testing Supplies Act of 2017.
F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES via F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
2017 · third_quarter · Q3
Medical Device Tax issue in H.R. 277 - American Health Care Act and H.R. 1628- Better Care Reconciliation Act
H.R. 3271- S.1914 - Protecting Access to Diabetic Testing Supplies Act of 2017 Medical Device Tax issue in H.R. 277 - American Health Care Act and H.R. 1628 - Better Care Reconciliation Act. . H.R. xxxx - Regulatory framework for in-vitro clinical tests (unnamed discussion draft, and Diagnostic Accuracy and Innovation Act).
H.R. 3271 and S.1914 - Protecting Access to Diabetic Testing Supplies Act of 2017.
F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES via F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
2017 · second_quarter · Q2
H.R. 771 and S.4 - Protecting Access to Diabetic Testing Supplies Act of 2015.
H. R. 771 and S.4 - Protecting Access to Diabetic Testing Supplies Act of 2015.
Medical Device Tax issue in H.R. 277 - American Health Care Act and H.R. 1628 - Better Care Reconciliation Act.
F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES via F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
2017 · first_quarter · Q1
H. R. 771 and S.4 - Protecting Access to Diabetic Testing Supplies Act of 2015.
H.R. 771 and S.4 - Protecting Access to Diabetic Testing Supplies Act of 2015. H.R. xxxx - Regulatory framework for in-vitro clinical tests (unnamed discussion draft, and Diagnostic Accuracy and Innovation Act).
Issues related to contracting for diabetes supplies by the VA.
F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES via F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
2016 · fourth_quarter · Q4
H.R.6-21st Century Cures Act; Yet to be introduced House proposal to have the FDA regulate laboratory developed tests; Yet to be introduced Senate proposal to have the FDA regulate laboratory developed tests; H.R. 771-Protecting Access to Diabetes Supplies Act of 2015; Yet to be introduced Senate proposal on Medicare competitive bidding proposal related to diabetes supplies.
H.R. 771 - Protecting Access to Diabetic Testing Supplies Act of 2015. Yet to be introduced Senate proposal on Medicare Competitive Bidding related to diabetes testing supplies.
F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES via F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
2016 · third_quarter · Q3
Yet to be introduced House proposal to have FDA regulate lab developed tests. Yet to be introduced Senate proposal to have FDA regulate lab developed tests.
HR 771: Protecting Access to Diabetic Testing Supplies Act of 2015. Yet to be introduced proposal on Medicare Competitive Bidding related to diabetes testing supplies. Legislation affecting Medicare payments for laboratory services.
H.R.6-21st Century Cures Act; Yet to be introduced House proposal to have the FDA regulate laboratory developed tests; Yet to be introduced Senate proposal to have the FDA regulate laboratory developed tests; H.R. 771-Protecting Access to Diabetes Supplies Act of 2015; Yet to be introduced Senate proposal on Medicare competitive bidding proposal related to diabetes supplies.
F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES via F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
2016 · second_quarter · Q2
Legislation affecting the Medicare DMEPOS competitive bidding program. Legislation affecting Medicare payment for laboratory services.
H.R.160-Protect Medical Innovation Act of 2015. S.149-Medical Device Access and Innovation Protection Act. HR.6-21st Century Cures Act. Yet to be introduced House proposal to have the FDA regulate laboratory developed tests. Yet to be introduced Senate proposal to have the FDA regulate laboratory developed tests. H.R. 771-Protecting Access to Diabetes Supplies Act of 2015. Yet to be introduced Senate proposal on Medicare competitive bidding proposal related to diabetes supplies. HCR Competitive Bidding. H.R.6-21st Century Cures Act; Yet to be introduced House proposal to have the FDA regulate laboratory developed tests; Yet to be introduced Senate proposal to have the FDA regulate laboratory developed tests; H.R. 771-Protecting Access to Diabetes Supplies Act of 2015; Yet to be introduced Senate proposal on Medicare competitive bidding proposal related to diabetes supplies. Monitored Congressional actions on HR 6, 21st Century Cures Act.
F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES via F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
2016 · first_quarter · Q1
H.R.160-Protect Medical Innovation Act of 2015 S.149-Medical Device Access and Innovation Protection Act
H.R.6-21st Century Cures Act Yet to be introduced House proposal to have the FDA regulate laboratory developed tests Yet to be introduced Senate proposal to have the FDA regulate laboratory developed tests H.R. 771-Protecting Access to Diabetes Supplies Act of 2015 Yet to be introduced Senate proposal on Medicare competitive bidding proposal related to diabetes supplies HPV NCCI Language Competitive bidding HR 771
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES via F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
2015 · fourth_quarter · Q4
H.R.160-Protect Medical Innovation Act of 2015 S.149-Medical Device Access and Innovation Protection Act H.R.6-21st Century Cures Act Yet to be introduced House proposal to have the FDA regulate laboratory developed tests Yet to be introduced Senate proposal to have the FDA regulate laboratory developed tests H.R. 771-Protecting Access to Diabetes Supplies Act of 2015 Yet to be introduced Senate proposal on Medicare competitive bidding proposal related to diabetes supplies
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES via F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
2015 · third_quarter · Q3
H.R.771-"Protecting Access to Diabetes Supplies Act of 2015" un-introduced Senate version of H.R.771 H.R.6-"21st Century Cures Initiative" un-introduced proposal to change FDA regulations of labs developed and In-vitro diagnostic tests
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES via F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
2015 · second_quarter · Q2
H.R.771-"Protecting Access to Diabetes Supplies Act of 2015 H.R.6-"21st Century Cures Initiative" un-introduced proposal to change FDA regulations of labs developed and In-vitro diagnostic tests H.R.160-"Protect Medical Innovation Act of 2015"
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES via F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
2015 · first_quarter · Q1
21st Century Cure Initiative (legislation was not introduced) Medical Electronic Data Technology Enhancement for Consumers' Health Act (not yet introduced) H.R.771-on reforming the competitive bidding program Department of Defense Appropriations Act of 2015
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES via F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
2014 · fourth_quarter · 4A
21st Century Cure Initiative (legislation was not introduced) S.2977-Medical Electronic Data Technology Enhancement for Consumers' Health Act H.R.3303-Sensible Oversight for Technology which Advances Regulatory Efficiency Act of 2013 H.R.4870-Department of Defense Appropriations Act of 2014 S.1429-Department of Defense Appropriations Act of 2014
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES via F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
2014 · fourth_quarter · Q4
21st Century Cure Initiative (legislation was not introduced) S.2977-Medical Electronic Data Technology Enhancement for Consumers' Health Act H.R.3303-Sensible Oversight for Technology which Advances Regulatory Efficiency Act of 2013 H.R.4870-Department of Defense Appropriations Act of 2014 S.1429-Department of Defense Appropriations Act of 2014
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES via F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
2014 · third_quarter · Q3
21st Century Cure Initiative (no legislation introduced yet); Reform to Medicare competitive bidding program (no legislation introduced yet); H.R.523 - Protecting Medicare Innovation Act of 2013
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES via F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
2014 · second_quarter · Q2
) HPV primary screening application before the FDA (no bill) 2) H.R.523-"Protect Medical Innovation Act of 2013" 3) S.232-"Medical Device Access and Innovation Protection Act"
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES via F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
2014 · first_quarter · Q1
H.R. 4015, the SGR Repeal and Medicare Provider Payment Modernization Act of 2014 H.R.2085-"Diagnostic Innovation Testing and Knowledge Advancement Act of 2013" Draft legislation to reform the Clinical Lab Fee Schedule H.R.523-"Protect Medical Innovation Act of 2013" S.232-"Medical Device Access and Innovation Protection Act"
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES via F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
2013 · fourth_quarter · Q4
H.R.2085-"Diagnostic Innovation Testing and Knowledge Advancement Act of 2013"; CY 2014 Medicare Physician Fee Schedule Rule (CMS/HHS); Draft legislation to reform the Clinical Lab Fee Schedule; H.R.523-"Protect Medical Innovation Act of 2013"; S.232-"Medical Device Access and Innovation Protection Act"; The Diabetes Access to Care Coalition; The CLFS Reform Coalition; and The PFS Pathology Payment Coalition.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES via F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
2013 · third_quarter · Q3
CMS competitive bidding program modification; Regulation of IVDs and LDTs; Protect Medical Innovation Act of 2013-HR 523; H.R.2085-"Diagnostic Innovation Testing and Knowledge Advancement Act of 2013"; CY 2014 Medicare Physician Fee Schedule Rule Proposal legislation (not yet introduced) to direct OIG study on the impact of DTS competitive bidding program on patient care
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES via F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
2013 · second_quarter · 2A
Issues relating to diagnostic laboratory testing.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES via F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
2013 · second_quarter · 2A
Issues relating to diagnostic laboratory testing.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES via F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
2013 · second_quarter · Q2
Issues relating to diagnostic laboratory testing.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES via F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
2013 · first_quarter · Q1
Issues relating to diagnostic laboratory testing.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES via F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
2012 · fourth_quarter · Q4
Proposed cuts to Part B reimbursement
Proposed cuts to Part B reimbursement; 340 reimbursement policy
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
(MED) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Alzheimer's and Influenza Preparedness
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
(MMM) Clinical Lab Fee Schedule reform and Medicare coverage of FDA approved breakthrough diagnostics and innovative diagnostics (preeclampsia)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
(HCR) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act. Issues related to the regulation of diagnostics
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA) and H.R. 1691 the Ensuring Patient Access to Critical Breakthrough Products Act of 2023 FY25 Labor, Health and Human Services, Education, and Related Agencies Appropriations Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS), U.S. Agency for International Development (USAID)
H.R. 2369 The Verifying Accurate Leading-edge IVCT Development Act, Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act, H. R. 5846 Protecting America from Seasonal and Pandemic, Influenza Act of 2023 (the Influenza Act) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA) and H.R. 1691 the Ensuring Patient Access to Critical Breakthrough Products Act of 2023 FY25 Labor, Health and Human Services, Education, and Related Agencies Appropriations Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS), U.S. Agency for International Development (USAID)
(HCR) H.R. 2369 The Verifying Accurate Leading-edge IVCT Development Act, Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act, and H. R. 5846 Protecting America from Seasonal and Pandemic Influenza Act of 2023 (the Influenza Act)
(MMM) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA), and HR 1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Agency for International Development (USAID)
FOR: Support authorization and appropriations for President's Emergency Plan for AIDS Relief (PEPFAR)
(HCR) H.R. 2369 The Verifying Accurate Leading-edge IVCT Development Act, Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act, SCREENS Act (HR 3916), issues related to 3rd party servicing of medical equipment (Right to Repair), H. R. 5846 Protecting America from Seasonal and Pandemic, Influenza Act of 2023 (the Influenza Act) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA) 1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE, State, Dept of (DOS), U.S. Agency for International Development (USAID), White House Office
FOR: Support authorization and appropriations for President's Emergency Plan for AIDS Relief (PEPFAR)
H.R. 2369 The Verifying Accurate Leading-edge IVCT Development Act, Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act, H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act. (HCR) H. R. 1305 Saving Us from Pandemic Era Resistance by Building a Unified Global Strategy Act of 2023", and issues related to influenzas preparedness Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA)
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE, State, Dept of (DOS), U.S. Agency for International Development (USAID), White House Office
(MMM) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA), and HR 1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE, State, Dept of (DOS), U.S. Agency for International Development (USAID), White House Office
HCR: The Verifying Accurate Leading-edge IVCT Development Act and Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE, State, Dept of (DOS), U.S. Agency for International Development (USAID), White House Office
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE, White House Office
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE, White House Office
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE, White House Office
H.R. 4128/S. 2209 The Verifying Accurate Leading-edge IVCT Development Act. H.R. 747/S.1018 The Access to Technology and Equipment for Same-day Tests Act. H.R.1436/S. 308 Protecting Providers Everywhere in America Act. H.R. 3635/S. 1974 Strengthening America's Strategic National Stockpile Act H.R. 3463/S.1693 Medical Supplies for Pandemics Act. Build Back Better Reconciliation Package Issues related to public health emergency preparedness
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE, White House Office
Medicare payment for clinical laboratories and diagnostic tests.
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Federal Emergency Management Agency (FEMA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE, White House Office
Medicare payment for clinical laboratories and diagnostic tests
none
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Medical Device Tax
H.R. 6102/S.3404 - The Verifying Accurate, Leading-edge IVCT Development Act; S.1895 - The Lower Health Care Costs Act; H.R.861 - End Surprise Billing Act of 2019. HR 4393- Advancing Access to Precision Medicine Act. HR 6201- Families First Coronavirus Response Act; HR 748 - Coronavirus Aid, Relief, and Economic Security Act
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
H.R. 6102/S.3404 - The Verifying Accurate, Leading-edge IVCT Development Act; S.1895 - The Lower Health Care Costs Act; H.R.861 - End Surprise Billing Act of 2019. HR 4393- Advancing Access to Precision Medicine Act. HR 6201- Families First Coronavirus Response Act; HR 748 - Coronavirus Aid, Relief, and Economic Security Act
H.R. 6102/S.3404 - The Verifying Accurate, Leading-edge IVCT Development Act; S.1895 - The Lower Health Care Costs Act; H.R.861 - End Surprise Billing Act of 2019. HR 4393- Advancing Access to Precision Medicine Act. HR 6201- Families First Coronavirus Response Act; HR 748 - Coronavirus Aid, Relief, and Economic Security Act
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Medicare payment for clinical laboratories and diagnostic tests; Medicare payment for patient self testing for prothrombin time; HR 3584 and S.3049, Laboratory Access for Beneficiaries Act
Appropriations for Department of Health and Human Services and Department of Veterans Affairs
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Appropriations for Department of Health and Human Services and Department of Veterans Affairs
H.R. 6102/S.3404 - The Verifying Accurate, Leading-edge IVCT Development Act; S.1895 - The Lower Health Care Costs Act; H.R.861 - End Surprise Billing Act of 2019. HR 4393- Advancing Access to Precision Medicine Act. HR 6201- Families First Coronavirus Response Act; HR 748 - Coronavirus Aid, Relief, and Economic Security Act
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Medicare payment for clinical laboratories and diagnostic tests; Medicare payment for patient self testing for prothrombin time; HR 3584 and S.3049, Laboratory Access for Beneficiaries Act)
H.R. xxxx - Discussion drafts of the Verifying Accurate, Leading-edge IVCT Development Act; S.1895 - The Lower Health Care Costs Act; H.R.861 - End Surprise Billing Act of 2019. H.R. 4393- Advancing Access to Precision Medicine Act
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Appropriations for Department of Health and Human Services and Department of Veterans Affairs
H.R. xxxx - Discussion drafts of the Verifying Accurate, Leading-edge IVCT Development Act; S.1895 - The Lower Health Care Costs Act; H.R.861 - End Surprise Billing Act of 2019.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Medical Device Tax
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Medical Device Tax
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
H.R. xxxx - Regulatory framework for in-vitro clinical tests (Diagnostic Accuracy and Innovation Act and Verifying Accurate, Leading-edge IVCT Development Act) HR 6378 / S. 2852 Pandemic All-Hazards Preparedness Reauthorization Act; Medicare payment for clinical laboratories and diagnostic tests, and Protecting Access to Medicare Act of 2014.
- S. 3476 - The PEPFAR Extension Act of 2018.

Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
H.R. xxxx: Regulatory framework for in-virtro clinical tests (Diagnostics Accuracy and Innovation Act Discussion Draft) Genetic testing coverage
H.R. 5786/S. 3024: Military Construction, Veterans Affairs, and Related Agencies Appropriations Bill 2019 H.R. xxxx /S. 3158: Department of Labor, Health, and Human Services, and Education, and Related Agencies Appropriations Bill 2019
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
H.R. xxxx: Regulatory framework for in-virtro clinical tests (Diagnostics Accuracy and Innovation Act Discussion Draft)
H.R. 4302 - Protecting Access to Medicare Act of 2014
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
S.1914 - Protecting Access to Diabetic Testing Supplies Act of 2017 H.R. 4302 - Protecting Access to Medicare Act of 2014
H.R. 1892 - The Bipartisan Budget Act of 2018
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Medical Device Tax issue in H.R. 1 - Tax Cuts and Jobs Act of 2017.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
H.R. 3271 and S.1914 - Protecting Access to Diabetic Testing Supplies Act of 2017.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
H.R. 771 and S.4 - Protecting Access to Diabetic Testing Supplies Act of 2015. H.R. xxxx - Regulatory framework for in-vitro clinical tests (unnamed discussion draft, and Diagnostic Accuracy and Innovation Act).
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
H.R. 771 and S.4 - Protecting Access to Diabetic Testing Supplies Act of 2015.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HR 771: Protecting Access to Diabetic Testing Supplies Act of 2015. S.4 - Protecting Access to Diabetes Supplies Act of 2016. Legislation affecting Medicare payments for laboratory services. WHO PQ Process for Diagnostics. Develop streamlined process to get QW modifier added to tests that are granted CLIA-waived status by the FDA.
Yet to be introduced House proposal to have FDA regulate lab developed tests. Yet to be introduced Senate proposal to have FDA regulate lab developed tests.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
H.R. 771 - Protecting Access to Diabetic Testing Supplies Act of 2015. Yet to be introduced Senate proposal on Medicare Competitive Bidding related to diabetes testing supplies.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE